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Type 1diabetes is one of themost commonchronic diseases of childhood.
Between 1989 and 2003, the incidence of type 1 diabetes in youth increased
at approximately 3.9% per year with a projected doubling of cases in
children aged <5 yr between 2005 and 2015 (1). This has substantial
impact on those affected, their families, on pediatric diabetes care, and
on national health care budgets. Much has changed over the last decade
in terms of management strategies in type 1 diabetes, however, as Edwin
Gale editorialized in 2005 that the challenges of diabetes remain much the
same (2). In short, there are more cases resulting in increasing disease years
characterized by greater medical and psychosocial complexity.
The Hvidoere International Study Group on Childhood Diabetes
evolved in 1994 during a meeting that was held in the immediate post
Diabetes Control and Complication Trial (DCCT, 3) era to discuss
strategies that could improve the quality of pediatric diabetes care
and thereby improve subsequent adult outcomes. The objectives and
mission statement of the Hvidoere group can be found on its website
http://www.hvidoeregroup.org/. In short, this unique collaboration of 26
pediatric diabetes centers from 23 countries (Europe, North America,
Japan, and Australia) has undertaken a series of research projects
investigating critical determinants for long-term outcome of type 1
diabetes care discriminating in terms of outcomes and which aspects of
care are universally effective. In all the Hvidoere studies, HbA1c was
analyzed centrally at the Steno Diabetes Center, Denmark. In the period
from 1997 to December 2002 HbA1c was analyzed using an automated
high pressure liquid chromatographic method (Bio-Rad Variant, Bio-Rad
Laboratories, Hercules, CA, USA) using the same calibrator lots as
the DCCT laboratory. From 2003 till now, HbA1c was analyzed by
the DCCT aligned TOSOH Automated Glycohemoglobin Analyzer
HLC-723G7, Tosoh Corporation, Tokyo, Japan.
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Five major studies have been undertaken, both cross-
sectional and longitudinal, serving this goal. The
findings detailed below show that these studies have led
to an internationally recognized remission parameter
(4) and have validated well-being and quality-of-life
(QOL) questionnaires (with relevant translation, (5).
The key thematic and practical findings of this body
of work (published in 28 peer reviewed medical and
scientific journals) are summarized in this review.
Key findings
1995 – Comparison of metabolic control in a
cross-sectional study of children and adolescents
with type 1 diabetes from 18 countries
The Hvidoere Study Group started with a cross-
sectional survey in 1995 in children and adolescents
with type 1 diabetes in an international context. The
purpose of the first study was to describe various
insulin regimens and metabolic control in children and
adolescents with type 1 diabetes in an international
context. This cross-sectional study involved 21 pedi-
atric diabetes centers (2873 children aged 0–18 yr) from
18 countries (6). The centrally measured overall mean
HbA1c was 8.6%, with a mean HbA1c of 8.3± 1.3%
in children under 11 yr compared with 8.9± 1.8%
in those aged 12–18 yr. The average prepubertal
dose of insulin was 0.65 units/kg/d; 60% of children
were receiving two injections per day (37% using
premixed insulins alone) and 37% of children were
receiving more than three injections per day. Major
and significant differences (center mean HbA1c values
ranged between 7.6± 1.4% and 10.2± 2.3%) were
observed between the centers which were not readily
explicable in terms of geography or staffing structure.
1998 – Metabolic control, QOL and insulin
injection regimens in an international survey of
adolescents with type 1 diabetes over 3 yr
The second study was intended to investigate cross-
sectionally the association of metabolic control
and QOL of adolescents. This was the first large
international study evaluating the relationship between
metabolic control and QOL among adolescents
with diabetes (10–18 yr) and their parents in 2101.
New international QOL assessment instruments were
developed and evaluated in order to assess family
burden, and parent and professional perspectives on
QOL (5, 8). This study showed that good metabolic
control is associated with better adolescent QOL and
less parent perceived family burden. Adolescent girls,
those of single parent families and ethnicminorities had
poorer metabolic control and poorer QOL Discordant
views relating to adolescent QOL, and family burden
were reported across adolescents, parents, and health
professionals groups and indicate the need to assess
all three perspectives (7, 9). This study showed that
better HbA1c was associated with better QOL for
adolescents and with a lesser perceived burden by
parents, however, as this was a cross-sectional study
it was not possible to determine a cause-and-effect
relation. It is likely that individuals with a higher QOL
may be better equipped physically and psychologically
to deal with the burden of diabetes management, hence
better QOL may facilitate better metabolic control
through improved self-care as part of positive circle.
Efforts to achieve optimal metabolic control now
appear justified on QOL as well as clinical grounds.
The study indicated the need for further studies to
evaluate the relationship between QOL and clinical
outcomes including specific aspects relating to QOL,
psychosocial issues, and vulnerable groups.
In addition, in order to investigate whether dif-
ferences in insulin management were associated with
metabolic differences across centers a longitudinal
study was conducted on children who participated
in both the first and second study. This study is related
to insulin injection regimens and metabolic control
including rates of hypoglycemia and changes in body
mass index (BMI) over the intervening 3 yr period.
The longitudinal component of the 1998 study was
limited to children and adolescents who were aged
8–15 yr of age in 1995. Of the 1538 eligible patients,
872 adolescents provided blood samples and data in
1998. This study involved 21 pediatric diabetes centers
from 17 countries. After the 3 yr period there was a
marked overall increase in insulin injection frequency
and the use of multiple injection (more than three
injections=multiple daily injections [MDI]) regimens
increased from 42 to 71% (10) The overall meanHbA1c
remained high (8.9% in both the 1995 11–18 yr old and
the 1998 12–18 yr old group). The change to MDI reg-
imens was associated with significantly increased rela-
tive mean insulin dose, a significantly increased BMI,
and approximate doubling of the rate of severe hypo-
glycemia without improved HbA1c values. Three cen-
ters significantly improved their mean HbA1c value, 4
centers significantly deteriorated, and the remaining 14
centers remain unchanged. The overall spread in center
mean HbA1c values was largely unchanged from 10.1
to 7.7%and insulin regimen showednoassociationwith
center outcome (11). Interestingly, those centers with
the lowestmeanHbA1c values also had the lowest rates
of severe hypoglycemia and reported better QOL (7).
2005 – Center differences: adolescent study
The purpose of the third study was to identify relevant
factors influencing these persisting center differences
with a special focus on diabetes team dynamic,
family dynamic, demographic, linguistic, and clinical
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factors. This cross-sectional study involved 21 pediatric
diabetes centers, 14 of which had been previously
involved in the 1998 study. This study was focused on
adolescents aged 11–18 yr. Data was obtained for 2093
adolescents. The overall mean HbA1c was 8.2± 1.4%
(12). Pooled data showed significant correlations
between HbA1c and numerous variables, the most
significant of which were metabolic target or goal
setting, family communication, and parent well-being.
Specifically, both parent and adolescent reported
HbA1c targets and diabetes care team unanimity on
HbA1c targets were very strong predictors of HbA1c
achieved. Those parents and adolescents with the
lowest HbA1c targets and the respective diabetes care
teams most united in their goals achieved the best
clinical results (13). Intensified insulin regimens (MDI
and continuous subcutaneous insulin infusion [CSII])
showed no significantly lower HbA1c compared with
twice daily free mixing (lowest HbA1c). Secondary
outcome analysis failed to show an association between
insulin regimen andBMI, rates of severe hypoglycemia,
and diabetic ketoacidosis (DKA). Parent well-being
was assessed using the World Health Organization
(WHO)-5 Questionnaire. This study showed that most
parents of children with diabetes (80%) report good
well-being on the WHO-5 scale, however, 20% had
poor scores (<50), and 8% had likely depression (<28)
(14). Adolescents of parents with good well-being
scores had significantly better HbA1c, fewer worries,
and lower impact of diabetes than those of parents
with poor well-being scores. In addition, maternal
well-being was significantly poorer than that of fathers.
Of the 14 centers involved in both studies, signifi-
cant changes were seen in only three centers with two
improving and one deteriorating between 1998 and
2005. The overall spread of center’s mean HbA1c was
somewhat less than in 1995 and 1998 varying from 7.4
to 9.2%. Center differences were unable to be explained
by demographic and clinical variables. When a sub-
analysis of the 14 centers involved in the 1998 studywas
undertaken those centers that demonstrated consis-
tently lowerHbA1c results were not found to be adopt-
ing any strategy that the other centers were also using.
2009 – Center differences: child study
Optimizing metabolic control in adolescents may be a
more challenging task because of many physiological
and psychological processes involved and therefore
the fourth study focused on children aged <11 yr.
There were many reasons to expect that the findings in
the 2005 adolescent cohort would not be recapitulated
in a cohort of children whose management was largely
undertaken by their parents. This study involved
1133 children from 18 centers with a comparable
methodology as the 2005 study (15). The overall mean
HbA1c was 8.0± 1.0%, slightly better than in the
adolescents, with a lower rate of severe hypoglycemia.
Best metabolic control was achieved for those <11 yr
in the same centers as in the previous studies. Themean
HbA1c values between centers varied between 7.3 and
8.9%. Again no association was observed between
center outcome and demographic, resource, or clinical
variables. Despite major changes in medical manage-
ment (>99% on analog insulins and 32.8% with CSII)
over the decade between the 1998 and 2009 studies,
the proportion of children in this age group achieving
HbA1c levels less than 8.0% had only increased from
41 to 53%. As with the 2005 adolescent study, the
younger patients achieving the best metabolic control
were receiving twice daily free-mixing insulin regimens
(HbA1c= 7.3± 0.5%). However, severe hypoglycemia
was extremely uncommon (96% of patients did not
experience it at all during the study window). When
it occur it was most likely to happen in the twice daily
free-mixing insulin group and least likely to happen
in the insulin pump group. Whether this was simply
an artifact of it occurring disproportionately in three
children (with 11 events), the free mixing group having
a mean HbA1c that was 0.5% lower than the insulin
CSII group, or whether it related the mode of insulin
delivery per se was not evident.
Lessons for team leaders: change is difficult
The first question that should be asked by team leaders
is how generalizable are the data from the Hvidoere
group and do they apply to my center? It should be
acknowledged that the Hvidoere study centers are not
necessarily representative of their respective countries.
It was never the intention of the Hvidoere study
group to present representative national data from 23
countries – rather the group has presented data from
26 centers in 23 countries and has studied variables
within those centers to see if they explain differences
in outcomes. The Hvidoere study group was not
looking to define national characteristics that predict
metabolic outcome, rather the group was investigating
varying behaviors/philosophies from clinical teams
that affect metabolic outcome – exploiting the varying
national contexts to provide a potentially greater
variance in those behaviors and philosophies. The
patients themselves were recruited in such a way as
to minimize the risk of selection bias. In the 1995
and 1998 studies (before the larger centers joined the
Hvidoere study group), all patients attending centers
were invited to participate. In the 1995 study, 67%
of all patients treated at the centers during that year
were included in the study and analysis of the HbA1c
determinations, made locally at the individual centers,
showed that there was no difference between the mean
HbA1c level of patients participating in the study and
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non-participants (10). In the 1998 study, samples and
information from 79% of the patients registered at the
centers were obtained. In the 2005 and 2009 studies,
patients were recruited sequentially as they attended
clinics over a specified 3month time frame. In the large
centers there were limits on the numbers of patients
recruited (up to 200), whereas in the smaller centers all
patients who presented in the specified time periodwere
approached. This strategy was adopted to avoid large
numbers of patients from only a few centers skewing
the results of the study group overall.
What is perhapsmost noteworthy of all theHvidoere
study tranches has been the inability of most centers to
change their ranking in terms of metabolic control.
While there has been an overall improvement in
metabolic control between 1995 and 2009, individual
centers have largely remained in the same relative
position within the group as a whole. Importantly,
teams that perform well do so consistently over time
and over various age-groups. Moreover, centers that
perform well are able to achieve better levels of
metabolic control with less hypoglycemia than other
centers. Thus, the DCCT finding that a lower HbA1c
is associated with higher rates of severe hypoglycemia
(3) appears to be no longer the case. This has also
been described by other groups (16). In the same
vein, the 2005 and 2009 Hvidoere studies did not
find associations between either severe hypoglycemia
or DKA and HbA1c at an individual level.
One Hvidoere center underwent a major restructure
of their entire clinical team and approach after the 1995
study (17). This radical restructuring has resulted in a
persistent change in the ranking. The consistency in
center ranking has remained despite major changes in
clinical practice and ongoing feedback from the various
Hvidoere studies. Team leaders have both immutable
and manageable variables that affect their clinical ser-
vice and outcomes. Immutable variables include the
demographic nature of their referral base (selective
vs. population-based, percentage of ethnic minority
groups, changing prevalence in age groups, etc.). There
are a plethora of studies showing associations between
demographic variables and outcomes at an individual
level, however, in both the 2005 and 2009 Hvidoere
studies patient characteristics did not explain differ-
ences in outcomes at a center level. Thus in our experi-
ence for a center as a whole ‘demography is not destiny’
and team leaders should not use this as an excuse to
explain away poor outcomes.Manageable variables on
the other hand, include the resources applied to service
delivery, nature of medical therapy, and philosophy of
care. Data from the 2005 study showed that increased
frequency of patient contact with doctors was associ-
ated with lower HbA1c values, whereas increased con-
tact with allied health staff was associated with higher
HbA1c values. The vast majority of contact between
doctors and patients is planned or scheduled and thus
the inference that more scheduled contact results in
better control is self-evident. Contact with allied health
staff though may be either planned or crisis-based and
thus it is difficult to draw much by way of conclusion
in terms of cause and effect from the above-mentioned
data. However, it appears a conservative conclusion
that more frequent scheduled clinic medical contact
is more effective than frequent potentially crisis-based
allied health contact in improving metabolic control.
The 2005 study also highlighted the importance of
24-h telephone support. These supports are usually
designed for crisis-based care to avoid DKA or major
hypoglycemia. It was surprising then to note that while
presence of such support resulted in significantly lower
center’s HbA1c (8.1 vs. 8.4%), it did not impact on
rates of either DKA or severe hypoglycemia between
centers.
Lessons for individual doctors: it’s not what
you do, it’s how you do it
As was concluded in both the 2005 and 2009 studies,
it appears that the way in which staff at a center apply
a given insulin regimen is more important in determin-
ingmetabolic outcomes than the regimen itself (13, 15).
While the DCCT showed the benefits of intensive dia-
betes therapy, many physicians subsequently focused
upon just the intensive insulin therapy aspect of the
DCCT care package. Hvidoere clinicians were not
immune to this trend of enthusiastic and non-reflective
uptake of MDI regimens in the early post-DCCT era.
Unfortunately, this change in clinical practice did not
improve medical control and resulted in increases in
BMI and severe hypoglycemia rates (10). There are
now numerous other national and group registry stud-
ies that have also reported a lack of association between
specific insulin types and regimens and metabolic
outcomes (18–24). The success of even themost sophis-
ticated of insulin regimens combined with continuous
glucose sensing still remains hostage to issues of patient
adherence and usage (25). Thus, despite the theoreti-
cal advantages, simply ‘intensifying’ or increasing the
complexity of an insulin regimen does not necessarily
guarantee an improved outcome for patients. Rather
it appears that the clinical and metabolic goals or tar-
gets that accompany any therapeutic regimen are more
important in determining outcomes.
Potential lessons can be learnt from those Hvidoere
centers that have consistently performed the best in
terms of metabolic control. The one center that has
consistently had the lowest HbA1c values from 1995
to 2009 is one of the smaller centers. The Hvidoere
member in question is highly charismatic and has a
very prescriptive, ‘recipe’-based approach to managing
diabetes in his clinic (26). He prescribes mostly twice
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daily free mixing injections of insulin and eschews,
a flexible approach to dietary intake. This does not
appear to be at the expense of either hypoglycemia or
QOL in his patient group. Although many aspects of
his practice are shared by other Hvidoere members, it
has proved very difficult to translate this total approach
into other contexts for a variety of reasons. However,
this experience is emblematic that consistently excellent
outcomes can be achieved by simple, ‘non-intensive’
insulin regimens that are underpinned by a strong
philosophy of care.
Lessons for members of teams: unanimity of
purpose is everything
Factor analysis of 2005 and 2009 studies showed that
the ‘big picture’ issues such as team target HbA1c
levels, team communication with families and family
function were more strongly associated with metabolic
outcomes when compared with ‘small picture’ issues
such as insulin type, insulin delivery, types of insulin
adjustment, variations in hypoglycemia management,
etc. Family perceptions of within-team communication
were also associated with HbA1c. The corollary of this
was that those teams who had agreed upon metabolic
targets or unanimity of purpose were more likely to
achieve better center outcomes than those teams who
had varied metabolic goals (13).
The 2005 study of adolescents showed that
maladaptive dietary patterns were extremely common
with all centers having at least 30% of patients who
reported occasional binge-eating and 11% binge-eating
at least once per week. Insulin omission to control
weight was rare and consistent across centers with
2–3% and 1% of patients reporting insulin omission
on a weekly and daily basis, respectively. Patients who
omitted insulin more frequently than once per week
had significantly poorer metabolic control. Physical
activity on the other hand appeared to have no impact
at all upon any of the clinical outcomes such as HbA1c,
BMI, rates of severe hypoglycemia, and DKA, though
it was associated with improved health perception (27).
Thus, teams that have unanimity of purpose and
that focus together upon major issues such as goals,
effective communication, family support, and dealing
with non-adherence appear to achieve better outcomes
than teams which are disunited and focused upon the
minutiae of their own areas of diabetes care expertise.
Lessons for families: effective teamwork wins
the day
Families where both parents are living together and
there is paternal employment had better metabolic
outcomes in the 2005 and 2009 studies (28). Just as for
teams, parent and child report of target HbA1c was
strongly associated with metabolic outcomes (13). The
other strongest determinant of outcome was whether
or not there was agreement between parent and child
as to who was responsible for blood glucose testing
(i.e., it did not actually matter who did the work of
glucose monitoring so long as both parties agreed
whose job it was) (28). Parent reported trend-based
insulin adjustment using several days of blood glucose
data was also associated with improved metabolic
control.Adolescent reported insulin adjustment had no
relationship toHbA1c, rates of hypoglycemia orDKA.
Adolescent perception of parental over-involvement in
diabetes care, however, was associated with poorer
outcomes. Synthesizing these various factors it would
appear that a target-driven approach, agreed upon
role responsibility, and ongoing parental involvement
appears to be associated with the best metabolic
outcomes. In addition, parental and particularly
maternal well-being is pivotal. Families should focus
holistically on the well-being of both the diabetic child
and parents.
Conclusions: toward personalized pediatric
diabetes care
In the two decades following the DCCT there has
been an understandable push to ‘intensify’ therapy
in children and adolescents with type 1 diabetes to
improve metabolic outcomes. This change in practice
has coincided with an increasing variety of new insulin
types and delivery devices. Over this period most pedi-
atric centers have experienced improvement in mean
HbA1c values with an average quantum of 0.5–1.0%.
Notwithstanding this overall improvement, the
treatment cause and effect relationships is somewhat
obscure and there remains a high proportion of chil-
dren and adolescents who are unable to achieve agreed
target HbA1c values. TheHvidoere studies undertaken
over this same time period have shed some light upon
what drives and conversely what impedes improved
clinical outcomes. While some aspects of the Hvidoere
group’s study findings are novel – particularly those
that relate to the center by center comparisons, other
findings at an individual level have been replicated in
other contexts. In particular, the association between
poorer metabolic outcomes with increased levels
of diabetes-related family conflict the benefits of a
treat-to-target approach and the lack of metabolic
benefit associated with an unbalanced emphasis solely
upon insulin delivery have been repeatedly described
in the pediatric diabetes literature (29–33).
A simple yet valuable conclusion from the combined
Hvidoere studies is that a ‘one size fits all’ approach to
diabetes care in both children and adolescents with type
1 diabetes is not effective. When the Hvidoere datasets
were either combined or analyzed center by center,
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metabolic outcomes showed little relationship with tra-
ditionalmedical or clinical resource variables employed
in each of the study tranches. This was evidenced by the
general persistence of center differences despite large-
scale changes in clinical practice. The aspect of clinical
practice that has changed the most between 1995 and
2009 was insulin regimen with increasing use of analog
insulins, MDI, and insulin pump therapy seen across
almost every center. While there appears to have been
an overall improvement in metabolic outcomes in Hvi-
doere group, patients between 1995 and 2009 (with
HbA1c levels dropping from the mid to low 8’s) at no
stage has metabolic control been able to be correlated
with insulin regimen. Thus dogmatic statements about
one insulin regimen being inherently superior to any
other are not supported by these findings and hence
would appear to be inaccurate. On the other hand, the
2005 study in particular highlighted some very impor-
tant ‘non-medical’ variables that were strongly associ-
ated with metabolic outcome. Both target setting and
effective communication within families were stronger
determinants of metabolic control than any other clin-
ical, team resource, ethnic, or demographic variable.
The challenge for our group now is to intervene
to try and improve outcomes in those centers that
have consistently struggled to attain good levels of
metabolic control. We plan to design an intervention
based upon a distillation of the findings summarized
above. We will then trial this intervention in an ‘all
of clinic approach’ for those centers who currently
have the highest mean HbA1c levels. We hypothesize
that although the intervention will be undertaken in
a variety of national and cultural contexts it will be
universally effective due to its empirical basis.
Therapeutic strategies in and of themselves are not
enough to obtain desired clinical outcomes. While
all clinical regimens have some clinical utility, it
is the underlying therapeutic philosophy based on
a qualified common training for all team members
delivering diabetes care and education to the families
that drives improvement. The clinical aphorism of
‘Ask for mediocrity and you will receive’ holds true.
Thus, it appears that the best results will be obtained
by physicians who are target-driven and teams and
families that have unanimity of purpose. Perhaps the
conclusions relating the best clinical practice drawn
from the entire body of work of the Hvidoere studies
can be best summarized as – be dogmatic about
outcome but flexible in approach.
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